Abstract
Objective: To investigate the efficacy and safety of ultra-early tirofiban administration in patients with branch atheromatous disease (BAD) who show no relief of neurological deficit symptoms after intravenous thrombolysis. Methods: A retrospective analysis was conducted on patients admitted to the Stroke Center of Zhengzhou People’s Hospital from January 2021 to December 2024, who met the diagnostic criteria for BAD, completed intravenous thrombolysis but had no symptomatic relief. According to whether they received ultra-early tirofiban treatment, the patients were divided into a tirofiban group and a control group. Patients were followed up to 90 days, the modified Rankin Scale (mRS) was used to evaluate their long-term clinical prognosis, symptomatic intracranial hemorrhage, other adverse events and deaths were recorded, and the efficacy and safety of the two groups were compared. Results: A total of 130 patients were enrolled, including 62 in the tirofiban group and 68 in the control group. The National Institute of Health Stroke Scale (NIHSS) scores of the tirofiban group at 24~72 h and 7 days after treatment were lower than those of the Control group [3 (2,5) vs 3 (3,6), 2 (1,4) vs 3 (2,4)], and the proportions of patients with mRS score ≤1 and mRS score ≤2 at 90 days in the tirofiban group were higher than those in the control group (66.13% vs 42.65%, 72.58% vs 54.41%), with statistically significant differences (all P<0.05). One patient in the tirofiban group developed symptomatic intracranial hemorrhage, while no symptomatic intracranial hemorrhage occurred in the control group. In terms of death events, 2 patients in the tirofiban group died, with the causes being pneumonia and pulmonary embolism secondary to deep vein thrombosis detachment after long-term bed rest respectively; 1 patient in the Control group died of post-stroke pulmonary infection. The incidence of other adverse events was 11.29% in the tirofiban group and 7.35% in the Control group, and statistical analysis showed no significant differences (all P>0.05). Conclusion: For patients with BAD who have no symptomatic relief after intravenous thrombolysis, ultra-early application of tirofiban can significantly improve the prognosis with relatively high safety.
Key words
branch atheromatous disease; tirofiban; prognosis; intravenous thrombolysis
Cite this article
Download Citations
LI Jiarong, ZHANG Ying, ZHU Lili, SONG Liang, YU Meng, LI Haoran, FU Shengqi.
Efficacy and Safety of Ultra-Early Use of Tirofiban in Branch Atheromatous Disease Patients Without Symptom Relief After Intravenous Thrombolysis[J]. Neural Injury and Functional Reconstruction. 2026, 21(10): 565-569 https://doi.org/10.16780/j.cnki.sjssgncj.20260366
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}